Dusan S Bogunovic

US Patent:

20110275089, Nov 10, 2011

Filed:

Feb 17, 2011

Appl. No.:

12/932068

Inventors:

Dusan Bogunovic - New York NY, US
Nina Bhardwaj - West Orange NJ, US
David O'Neill - New York NY, US

International Classification:

C12Q 1/68
C12Q 1/06

US Classification:

435 614, 435 34, 435 39

Abstract:

Cellular and genetic signatures and methods of using same for subcategorizing stage III melanoma tumors are described herein. The signatures and methods are particularly useful with regard to establishing more distinct criteria on which basis to differentiate stage IIIB and IIIC melanoma patients. Assessment of the cellular and genetic signatures of a melanoma sample using methods described herein yields information on which basis differential survival duration and sensitivity to various cancer therapies can be predicted for a Stage IIIB or Stage IIIC melanoma patients. As described herein, gene expression profiling, determination of mitotic index (MI), and quantification of tumor infiltrating leukocytes (TILs) and CD3+ cells in metastatic lesions may be utilized to predict or assess drug response, drug sensitivity, and clinical outcome in metastatic melanoma patients.